

SUPPLEMENTAL FILE

**Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with
EMAST-Positive Stage II/III Colorectal Cancer**

Yasushi Hamaya¹, Carla Guarinos^{1,2}, Stephanie S. Tseng-Rogenski¹, Moriya Iwaizumi¹,
Ritabrata Das³, Rodrigo Jover², Antoni Castells⁴, Xavier Llor⁵, Montserrat Andreu⁶, John M.
Carethers¹

¹Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America; ²Unidad de Gastroenterología, Hospital General Universitario de Alicante, Alicante Spain; ³Biostatistics Department, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America; ⁴Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, University of Barcelona, Barcelona, Spain; ⁵Division of Gastroenterology, Department of Medicine, Yale University, New Haven, Connecticut, United States of America; ⁶Department of Gastroenterology, Hospital del Mar, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Pompeu Fabra University, Barcelona, Catalonia, Spain

Supplemental Tables

Table A. Clinical characteristics of CRC patients segregated by EMAST status, inclusive of MSI-H patients.

	All (N=230)	EMAST (N=102)	Non-EMAST (N=128)	P value
Age (years), median (range)	71 (22-93)	71 (40-93)	71 (22-93)	
Sex				
Female	96	37	59	
Male	134	65	69	0.141
Tumor site				
proximal	95	42	53	
distal	135	60	75	1.00
5-FU chemotherapy				
With	94	34	60	
Without	136	68	68	0.0433
Stage				
II	112	51	61	
III	118	51	67	0.791
MSI status				
MSI-H	30	20	10	
MSI-L/MSS	200	82	118	0.00832

MSI=microsatellite instability; H=high; L=low, MSS=microsatellite stable

Table B. Stratified log-rank test for comparing EMAST and 5-FU status.

All CRCs—P-values (n=230)

	5-FU + no EMAST	no 5-FU + EMAST
5-FU + EMAST	0.471	0.0186
no 5-FU + no EMAST	0.0196	0.58

CRCs without MSI-H—P-values (n=200)

	5-FU + no EMAST	no 5-FU + EMAST
5-FU + EMAST	0.474	0.034
no 5-FU + no EMAST	0.043	0.68

Supplemental Figures




Fig. A. Kaplan-Meier plots of cumulative overall survival in patients segregated by EMAST status. (A) Cumulative overall survival of all patients without MSI-H separated by EMAST status ($P=0.678$, log-rank test). (B) Cumulative overall survival of all non-MSI-H patients receiving adjuvant 5-FU separated by EMAST status ($P=0.474$, stratified log-rank test). (C) Cumulative overall survival of all non-MSI patients who did not receive adjuvant 5-FU chemotherapy, separated by EMAST status ($P=0.680$, stratified log-rank test).




Fig. B. Alternative survival plots for EMAST and non-EMAST patients, according to Royston *et al. J Natl Cancer Inst.* 2008;100:92-97.